NCT06184841View on ClinicalTrials.gov

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

October 18, 2023

Study Completion Date

December 1, 2023

Conditions
Hepatic Arterial Infusion ChemotherapyLiver MetastasesEsophageal Squamous Cell Carcinoma
Interventions
DRUG

HAIC combined with intravenous PD-1

Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Peking University Cancer Hospital & Institute

OTHER

NCT06184841 - HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter